The Efficacy of Topical Interferon Alpha 2b Treatment in Refractory Vernal Keratoconjunctivitis

REFERENCES

• Bonini S, Sacchetti M, Mantelli F, Lambiase A. Clinical grading of vernal keratoconjunctivitis. Curr Opin Allergy Clin Immunol. 2007;7:436–441.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Motterle L, Bortolotti M. Allergy and the eye. Clin Exp Immunol. 2008;153 (Suppl 1):17–21.
   PubMedGoogle Scholar
• Bonini S, Lambiase A, Sgrulletta R, Bonini S. Allergic chronic inflammation of the ocular surface in vernal keratoconjunctivitis. Curr Opin Allergy Clin Immunol. 2003;3:381–387.
   PubMed Web of Science ®Google Scholar
• Gupta V, Sahu PK. Topical cyclosporin A in the management of vernal keratoconjunctivitis. Eye (Lond). 2001;15(Pt 1):39–41.
   PubMedGoogle Scholar
• Bremond-Gignac D, Donadieu J, Leonardi A, et al. Prevalence of vernal keratoconjunctivitis: a rare disease? Br J Ophthalmol. 2008;92:1097–1102.
   PubMed Web of Science ®Google Scholar
• Saraçlar Y, Yigit S, Adalioglu G, Tuncer A, Tunçbilek E. Prevalence of allergic diseases and influencing factors in primary-school children in the Ankara Region of Turkey. J Asthma. 1997;34:23–30.
   PubMed Web of Science ®Google Scholar
• Attas-Fox L, Barkana Y, Iskhakov V, et al. Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study. Curr Eye Res. 2008;33:545–549.
   PubMed Web of Science ®Google Scholar
• Bonini S, Coassin M, Aronni S, Lambiase A. Vernal keratoconjunctivitis. Eye (Lond). 2004;18:345–351.
   PubMed Web of Science ®Google Scholar
• Hodges MG, Keane-Myers AM. Classification of ocular allergy. Curr Opin Allergy Clin Immunol. 2007;7:424–428.
   PubMedGoogle Scholar
• Mantelli F, Santos MS, Petitti T, et al. Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis. Br J Ophthalmol. 2007;91:1656–1661.
   PubMed Web of Science ®Google Scholar
• Akpek EK, Hasiripi H, Christen WG, Kalayci D. A randomized trial of low-dose, topical mitomycin-C in the treatment of severe vernal keratoconjunctivitis. Ophthalmology. 2000;107:263–269.
   PubMed Web of Science ®Google Scholar
• Ozcan AA, Ersoz TR, Dulger E. Management of severe allergic conjunctivitis with topical cyclosporin a 0.05% eyedrops. Cornea. 2007;26:1035–1038.
   PubMed Web of Science ®Google Scholar
• Huerva V, Mangues I. Treatment of conjunctival squamous neoplasias with interferon alpha 2ab. J Fr Ophtalmol. 2008;31:317–325.
   PubMed Web of Science ®Google Scholar
• Mackensen F, Max R, Becker MD. Interferon therapy for ocular disease. Curr Opin Ophthalmol. 2006;17:567–573.
   PubMed Web of Science ®Google Scholar
• Swieter M, Ghali WA, Rimmer C, Befus D. Interferon-alpha/beta inhibits IgE-dependent histamine release from rat mast cells. Immunology. 1989;66:606–610.
   PubMedGoogle Scholar
• Bissonnette EY, Chin B, Befus AD. Interferons differentially regulate histamine and TNF-alpha in rat intestinal mucosal mast cells. Immunology. 1995;86:12–17.
   PubMedGoogle Scholar
• Pung YH, Vetro SW, Bellanti JA. Use of interferons in atopic (IgE-mediated) diseases. Ann Allergy. 1993;71:234–238.
   PubMedGoogle Scholar
• Kimata H, Akiyama Y, Kubota M, Furusho K. Interferon-alpha treatment for severe atopic dermatitis. Allergy. 1995;50:837–840.
   PubMedGoogle Scholar
• Kocabeyoglu S, Bozkurt B, Bilen O, Irkec M, Orhan M. Serum allergen specific immunoglobulin E levels in patients with allergic conjunctivitis. Eur J Ophthalmol. 2008;18:675–679.
   PubMedGoogle Scholar
• Cao B, Chen XP, Zhu P, Ding L, Guan J, Shi ZL. Inhibitory effect of interferon-alpha-2b on expression of cyclooxygenase-2 and vascular endothelial growth factor in human hepatocellular carcinoma inoculated in nude mice. World J Gastroenterol. 2008;14:6802–6807.
   PubMed Web of Science ®Google Scholar
• Aman MJ, Tretter T, Eisenbeis I, et al. Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes. Blood. 1996;87:4731–4736.
   PubMed Web of Science ®Google Scholar
• Schandené L, Del Prete GF, Cogan E, et al. Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells. J Clin Invest. 1996;97:309–315.
   PubMed Web of Science ®Google Scholar
• Miyazaki D, Tominaga T, Yakura K, et al. Conjunctival mast cell as a mediator of eosinophilic response in ocular allergy. Mol Vis. 2008;14:1525–1532.
   PubMed Web of Science ®Google Scholar
• Aldebert D, Lamkhioued B, Desaint C, et al. Eosinophils express a functional receptor for interferon alpha: inhibitory role of interferon alpha on the release of mediators. Blood. 1996;87:2354–2360.
   PubMed Web of Science ®Google Scholar
• Fukuda K, Kumagai N, Fujitsu Y, Nishida T. Fibroblasts as local immune modulators in ocular allergic disease. Allergol Int. 2006;55:121–129.
   PubMedGoogle Scholar
• Huerva V, Sánchez MC, Mangues I. Tumor-volume increase at beginning of primary treatment with topical interferon alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia. J Ocul Pharmacol Ther. 2007;23:143–145.
   PubMedGoogle Scholar
• Finger PT, Sedeek RW, Chin KJ. Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex. Am J Ophthalmol. 2008;145:124–129.
   PubMed Web of Science ®Google Scholar
• Schechter BA, Schrier A, Nagler RS, Smith EF, Velasquez GE. Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b. Cornea. 2002;21:6–11.
   PubMed Web of Science ®Google Scholar
• Vann RR, Karp CL. Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia. Ophthalmology. 1999;106:91–97.
   PubMed Web of Science ®Google Scholar
• Schechter BA, Koreishi AF, Karp CL, Feuer W. Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b. Ophthalmology 2008;115:1291–1296, 6 e1.
   PubMedGoogle Scholar
• Sato M, Yoshida H, Yanagawa T, et al. Therapeutic effect of human fibroblast interferon on premalignant lesions arising in oral mucosa. A pilot study. Int J Oral Surg. 1985;14:184–194.
   PubMedGoogle Scholar
• Ohashi Y, Ebihara N, Fujishima H, et al. A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther. 2010;26:165–174.
   PubMed Web of Science ®Google Scholar
• Kheirkhah A, Zavareh MK, Farzbod F, Mahbod M, Behrouz MJ. Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis. Eye (Lond). 2011;25:872–880.
   PubMed Web of Science ®Google Scholar